Please use this identifier to cite or link to this item:
Title: Multiple vertebral fractures after suspension of denosumab. A series of 56 cases
Authors: Sosa Henríquez, Manuel José 
Torregrosa, Oscar
Déniz, Alejandro
Saavedra Santana, Pedro 
Ortego, Norberto
Turrión, Ana
Pérez Castrillón, José Luis
Díaz-Curiel, Manuel
Gómez-Alonso, Carlos
Martínez, Guillermo
Antonio Blázquez, José
Olmos-Martínez, José Manuel
Etxebarria, Íñigo
Caeiro, José Ramón
Mora-Peña, Damián
UNESCO Clasification: 32 Ciencias médicas
3201 Ciencias clínicas
Keywords: Vertebral fractures
Case report
Issue Date: 2021
Journal: International Journal of Clinical Practice 
Abstract: Denosumab is a monoclonal antibody approved for the treatment of postmenopausal osteoporosis. The withdrawal of denosumab produces an abrupt loss of bone mineral density and may cause multiple vertebral fractures (MVF). Objective: The objective of this study is to study the clinical, biochemical, and densitometric characteristics in a large series of postmenopausal women who suffered MVF after denosumab withdrawal. Likewise, we try to identify those factors related to the presence of a greater number of vertebral fractures (VF). Patients and Methods: Fifty-six patients (54 women) who suffered MVF after receiving denosumab at least for three consecutive years and abruptly suspended it. A clinical examination was carried out. Biochemical bone remodelling markers (BBRM) and bone densitometry at the lumbar spine and proximal femur were measured. VF were diagnosed by magnetic resonance imaging MRI, X-ray, or both at dorsal and lumbar spine. Results: Fifty-six patients presented a total of 192 VF. 41 patients (73.2%) had not previously suffered VF. After discontinuation of the drug, a statistically significant increase in the BBRM was observed. In the multivariate analysis, only the time that denosumab was previously received was associated with the presence of a greater number of VF (P =.04). Conclusions: We present the series with the largest number of patients collected to date. 56 patients accumulated 192 new VF. After the suspension of denosumab and the production of MVF, there was an increase in the serum values of the BBRM. The time of denosumab use was the only parameter associated with a greater number of fractures.
ISSN: 1368-5031
DOI: 10.1111/ijcp.14550
Source: International Journal of Clinical Practice [ISSN 1368-5031], v. 75(10), e14550, (Octubre 2021)
Appears in Collections:Artículos
Adobe PDF (544,56 kB)
Show full item record


checked on Oct 2, 2022

Page view(s)

checked on Aug 27, 2022


checked on Aug 27, 2022

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.